Abstract:Mateusz Szyma&nacuteski, 1, 2 Ma&lstrokgorzata M Skiba, 2 Ma&lstrokgorzata Piasecka, 2 Alina Olender 3 1 Human Anatomy Department, Medical University, Lublin, Poland; 2 Intensive Care Unit, Stefan Cardinal Wyszy&nacuteski District Specialist Hospital, Lublin, Poland; 3 Chair and Department of Medical Microbiology, Medical University, Lublin, Poland Correspondence: Ma&lstrokgorzata M Skiba, Intensive Care Unit, Stefan Cardinal Wyszy&nacuteski District Specialist Hospital, Al. Kra&sacutenicka 100, Lublin, 20-718, Poland, Tel +48 81 537 46 60, Email Background: The difficulties in attaining effective antibiotic therapy arising from the multidrug resistance of Gram-negative bacilli compel the exploration of new possibilities for synergistic interactions among existing antibiotics. Research Design and Methods: An analysis was conducted to assess the efficacy of two antibiotic therapy regimens in the treatment of infections caused by Klebsiella pneumoniae strains producing carbapenemases (MBL). Two patient groups were considered: Group A – individuals in whom the treatment of infection involved the application of ceftazidime-avibactam in combination with aztreonam. Group B comprised patients subjected to an alternative antibiotic therapy regimen. Results: In the group subjected to the treatment regimen involving ceftazidime-avibactam and aztreonam, as compared to alternative antibiotic combinations, a statistically lower mortality rate during the course of treatment and a faster clinical response to the administered therapy were evident. Conclusion: The results obtained may be applicable to routine in vitro assays performed and serve as valuable guidance for the potential utilization of the positive effect of antibiotic therapy through the synergy between ceftazidime-avibactam and aztreonam. The selection of antibiotics employed in the therapy of invasive infections caused by K. pneumoniae influences the ultimate treatment outcome. Keywords: synergism, ceftazidime-avibactam, aztreonam, multidrug-resistant K. pneumoniae, metal-beta-lactamases Resistance to carbapenems among Gram-negative bacilli from the Enterobacterales family, as well as non-fermenting bacilli, currently constitutes a predominant challenge in the treatment of nosocomial infections. In recent years, there has been a significant increase in both the number of infections and the number of deaths caused by multidrug-resistant bacterial strains. The mortality rate in cases of infections caused by multidrug-resistant strains may be up to four times higher compared to infections caused by susceptible strains. Resistance to carbapenems is usually associated with resistance to all beta-lactam antibiotics, which significantly limits therapeutic options. This resistance may result from the production of carbapenemases, ie enzymes that degrade carbapenems and other beta-lactam antibiotics. The exception here is metal-beta-lactamases (MBLs) – class B carbapenemases, which by definition degrade all beta-lactam antibiotics except monobactams, ie aztreonam. The production of carbapenemases by bacteria is often associated with the resistance to other antibiotic groups, and this results in limited or even no therapeutic options for the treatment of infections. In the case of MBL(+), aztreonam lacks clinical activity due to the frequent additional presence of ESBLs (extended-spectrum beta-lactamases) or AmpC-type (chromosomal cephalosporinase) beta-lactamases that hydrolyze it. 1–5 In the treatment of infections caused by multidrug-resistant strains of Gram-negative bacilli, antibiotics with diverse mechanisms of action and targets are employed. Disparities in the pharmacokinetic-pharmacodynamic profile arise not only from differences in the molecular structure of the drug molecule. Significant factors contributing to these differences include the degree of binding to plasma proteins, half-life, interactions with other drugs, timing of administration (particularly for beta-lactam antibiotics), volume of distribution, etc. 6 It is crucial to explore effective therapeutic options for treating infections caused by multidrug-resistant strains as well as to develop tools for rapid identification of highly virulent strains, which could significantly reduce the risk of epidemics. 7 Detailed information on issues related to the diagnosis, treatment, and monitoring of infections caused by multidrug-resistant microorganisms, including MBL(+) Gram-negative bacilli, can be found in the available literature. One of the therapeutic options mentioned concerns the combination of ceftazidime-avibactam with aztreonam. This therapy is still in -Abstract Truncated-

Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella Pneumoniae

Aztreonam-avibactam May Not Replace Ceftazidime/avibactam: the Case of KPC-21 Carbapenemase and Penicillin-Binding Protein 3 with Four Extra Amino Acids

Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam Against Carbapenem-Resistant Enterobacteriaceae

Effects of Klebsiella Pneumoniae Carbapenemase Subtypes, Extended-Spectrum Β-Lactamases, and Porin Mutations on the in Vitro Activity of Ceftazidime-Avibactam Against Carbapenem-Resistant K. Pneumoniae

Aztreonam/avibactam Effect on Pharmacodynamic Indices for Mutant Selection of Escherichia Coli and Klebsiella Pneumoniae Harbouring Serine- and New Delhi Metallo-Β-lactamases.

In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam Against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China

Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia

Evaluation of ceftazidime-avibactam efficacy in gram negative bacteria

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates

Resistance to Aztreonam-Avibactam Due to CTX-M-15 in the Presence of Penicillin-Binding Protein 3 with Extra Amino Acids in Escherichia Coli

Antimicrobial Activity of Ceftazidime-Avibactam Against KPC-2-producing Enterobacterales: a Cross-Combination and Dose-Escalation Titration Study with Relebactam and Vaborbactam

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021

Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-Positive Klebsiella pneumoniae MBL+, NDM+

In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains

In Vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing Blakpc or Blandm

<i>In Vitro</i> Activity Comparison of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections With Carbapenem-Resistant Organisms in China

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales